This website uses own and third-party cookies to gather information on the use of the website, to improve the quality of services and to offer you a better user experience. Please accept or reject cookies on this website by choosing one of the following links:. The purpose of this Cookies Policy is to provide you with clear and precise information on the Cookies that are used on our website. A cookie is a file that is downloaded to your computer or other device when accessing certain web pages that collects information about your browsing on said website. Cookies are used to gather information about your browsing to facilitate your use of the website, to offer you a better user experience and to improve our website.
|Published (Last):||26 August 2018|
|PDF File Size:||2.19 Mb|
|ePub File Size:||12.83 Mb|
|Price:||Free* [*Free Regsitration Required]|
Contract Manufacturing Finance. The incorporation of this new main shareholder comes after Infarco, the previous major partner, decided to successfully culminate their strategic business venture. Therefore, this new partnership represents an important breakthrough for 3P.
We are extremely enthusiastic to work with Keensight Capital at such a crucial moment for our industry. With their global footprint and their expertise in the biologics field, I am highly confident that Keensight team will help us reach significant milestones in the coming years.
We look forward to partnering with 3P in its efforts to further expand its scale and impact in the healthcare biotech field while retaining the entrepreneurial culture that helped 3P become what it is today.
We are particularly excited to be working with such a talented team of individuals, many of whom have been together since the very beginning of 3P. One of the distinguishing features of 3P has always been transparency. Almac Group reports further growth during period of global expansion. Recipharm CEO sells shares but remains committed and significant holder.
Sterling Pharma Solutions more than doubles its sales. Companies 3P Biopharmaceuticals. PCI expands in Canada with clinical trial services acquisition. Piramal expands API contract manufacturing in Canada. Bristol-Myers Squibb and Catalent close Italian manufacturing deal. NervGen trades shares to CMO partner in exchange for clinical supply order.
GVK Bio reveals whether research or development services perform better.
3P Biopharmaceuticals finds major new investor
The technology employed by In3Bio produces new molecules specific to one or multiple growth factors at the same time. In this way, these new candidates have demonstrated a wide potential in the treatment of different cancer indications using established preclinical models, opening the door for developing effective anti-tumor therapy. Sign in. Forgot your password? Get help. Password recovery. COVID to setback blockchain implementation in global pharmaceutical supply chains.
Contract Manufacturing Finance. The incorporation of this new main shareholder comes after Infarco, the previous major partner, decided to successfully culminate their strategic business venture. Therefore, this new partnership represents an important breakthrough for 3P. We are extremely enthusiastic to work with Keensight Capital at such a crucial moment for our industry.
3P Biopharmaceuticals, In3Bio to Collaborate in Novel Anti-Tumor Treatment Development